Dermaq Featured as Panelist at Melbourne Let the Pep Talk Daxxify Launch

We are proud to announce that our Dermaq Aesthetics, was invited as a featured panelist at the exclusive “Melbourne Let the Pep Talk” event for Daxxify® by Teoxane. This prestigious invitation recognises our expertise and leadership in aesthetic medicine.

The Melbourne Let the Pep Talk event drew leading aesthetic practitioners from across Australia

Introducing Daxxify: A New Era in Neurotoxin Technology

Daxxify represents a revolutionary advancement in aesthetic medicine as the first and only toxin formulated with a proprietary peptide. This groundbreaking innovation marks a significant departure from traditional botulinum toxin formulations, offering a unique clinical profile that’s setting new standards in the industry.

What Makes Daxxify Different?

Unlike conventional neurotoxins, Daxxify’s innovative formulation stabilises botulinum toxin without any human or animal byproducts. This clean, modern approach to formulation science is the result of over 20 years of dedicated research and development.

The key differentiators include:

• 🧪 Proprietary Peptide Technology: The peptide is integral to the innovation, providing unique stabilisation properties
• 📦 Pure Excipients: The carefully selected excipients contribute to the product’s distinctive profile
• 🚀 Breakthrough Formulation: A completely new approach to neurotoxin formulation that delivers exceptional results

The Science Behind Daxxify: Understanding Peptide-Exchange Technology

Daxxify (daxibotulinumtoxinA-lanm) represents a paradigm shift in neuromodulator science. As a botulinum toxin type A product, it shares the fundamental mechanism of action with other neurotoxins - temporarily reducing muscle activity to soften dynamic wrinkles and treat glabellar lines. However, its unique peptide-exchange technology (PXT) sets it apart from conventional botulinum toxin formulations.

Clinical Profile and Efficacy

The proprietary 35-amino acid peptide in Daxxify serves as a novel stabilising excipient, eliminating the need for human serum albumin or animal-derived proteins found in traditional neurotoxin formulations. This innovative approach has demonstrated several clinical advantages in extensive trials:

• Extended Duration of Effect: Clinical studies, including the landmark SAKURA trials, have shown median duration of effect up to 6 months for moderate to severe glabellar lines, with some patients experiencing results lasting up to 9 months
• Rapid Onset of Action: Many patients report visible wrinkle reduction within 24-48 hours post-injection
• Consistent Clinical Results: The peptide stabilisation technology provides uniform product consistency and predictable outcomes
• High Patient Satisfaction: Studies report over 95% patient satisfaction rates at 4 weeks post-treatment

The Peptide Advantage in Aesthetic Medicine

The proprietary peptide technology works through a unique mechanism that enhances the delivery and efficacy of the botulinum toxin type A molecule. Key aspects include:

• Enhanced Cellular Uptake: Improved binding affinity to nerve terminals
• Optimised Diffusion Profile: Reduced spread from injection sites for precise treatment
• Stability Without Refrigeration: Maintains potency for extended periods
• Pure Formulation: Absence of human or animal-derived components potentially reducing immunogenicity

Two Decades of Research Excellence

At the heart of Daxxify is a commitment to advancing aesthetic medicine through rigorous scientific research. The development involved over 20 years of research, resulting in a comprehensive understanding of peptide-mediated botulinum toxin delivery. This extensive research program included:

• Multiple phase III clinical trials with thousands of participants
• Comprehensive safety evaluations across diverse patient populations
• Long-term efficacy studies demonstrating sustained results
• Regulatory approval from the FDA and international health authorities including the TGA

The proprietary peptide technology represents a fundamental shift in how wrinkle relaxers and neuromodulators are formulated and delivered, offering aesthetic practitioners and their patients a new option for treating facial lines with potentially longer-lasting results.

The Melbourne Let the Pep Talk Event

The “Melbourne Let the Pep Talk” event, held at Two Ton Max in North Melbourne, brought together Australia’s leading aesthetic practitioners with international experts to discuss the science, strategy, and bold new ideas behind Daxxify. The tagline “Let the Pep Talk” cleverly references the proprietary peptide at the heart of Daxxify’s innovation.

Industry professionals networking and celebrating the Australian launch of Daxxify

Distinguished Panel and Speakers

We joined an impressive panel of experts at this exclusive event:

Other Melbourne Panelists:

• Dr. Scott Horsborough
• Aska Lagodko RN
• Dr. Nik Davies

Event Moderator:

• Dr. Cara McDonald – Dermatologist and educator specialising in advanced aesthetic techniques

International Guest Speakers:

• Dr. Michael Kane, MD, FACS – World-renowned plastic surgeon and early Daxxify investigator
• Olivia Salmen, NP-C – Advanced aesthetic injector, Revance medical trainer, and international speaker

As a featured panelist, Dermaq contributed to the scientific discussion with insights into clinical observations and techniques related to neuromodulator treatments. Her participation alongside these distinguished international and Australian professionals underscores her position as a respected voice in the aesthetic medicine community.

The expert panel featuring Dermaq discussing clinical applications of Daxxify

The distinguished panel of experts discussing the revolutionary science behind Daxxify

Professional Excellence in Aesthetic Medicine

Dermaq selection as a panelist for this prestigious event reflects our standing in the aesthetic medicine community. Our participation in high-level educational forums like the Melbourne Let the Pep Talk demonstrates:

• Commitment to staying current with scientific advances in neuromodulator technology
• Active engagement with international research and clinical findings
• Contribution to professional discourse on evidence-based aesthetic medicine
• Leadership in advancing education standards within the Australian aesthetic medicine community

Looking Forward

The launch of Daxxify in Australia represents a significant milestone in the evolution of neuromodulator treatments. Dermaq’s selection to participate in this historic educational event acknowledges her expertise and contributions to the field of aesthetic medicine.

Dermaq with the Teoxane family at the Melbourne Let the Pep Talk event

The knowledge gained from this landmark event contributes to the ongoing advancement of aesthetic medicine education in Australia, as practitioners like those at Dermaq continue to engage with the latest scientific developments in the field.

The Future of Aesthetic Medicine

Events like the Melbourne Let the Pep Talk showcase the rapid evolution occurring in aesthetic medicine. The scientific presentations and panel discussions highlighted how innovations like peptide-exchange technology are advancing the field, providing practitioners with new insights into the science of neuromodulators. Dermaq’s participation in this educational forum demonstrates the importance of continuous professional development in delivering evidence-based aesthetic medicine.

Note: Daxxify® (daxibotulinumtoxinA-lanm) is a prescription medicine. This article is for educational purposes only and describes proceedings from a professional medical conference.

The Melbourne Let the Pep Talk event marked an important moment in Australian aesthetic medicine, bringing together local and international experts to share knowledge about the latest advances in neuromodulator science.